Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Cartalax

A three-amino-acid Khavinson-series short peptide whose published evidence is cell-culture work, not human joint or cartilage outcomes.

L0Anecdote onlyNot approved for this use
Full profile

B7-33

A synthetic single-chain peptide derived from the relaxin-2 B-chain that signals at RXFP1; evidence is cell and animal work only.

L1Theory onlyNot approved for this use
Full profile

How far human research has progressed

Cartalax

Cell-culture research only

B7-33

Preclinical (cell and rodent studies)

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Cartalax

Not separately assessed; see the full profile.

B7-33

Not separately assessed; see the full profile.

Human research context

Cartalax

Cell-culture research only

B7-33

Preclinical (cell and rodent studies)

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Cartalax

Strength of the human efficacy evidence4 of 100 evidence strength

B7-33

Strength of the human efficacy evidence2 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Cartalax

Strength of the animal and lab evidence26 of 100 evidence strength

B7-33

Strength of the animal and lab evidence30 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Cartalax

Strength of the human safety evidence6 of 100 evidence strength

B7-33

Strength of the human safety evidence4 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Cartalax

Check jurisdiction-specific details in the profile.

Not an approved medicine in any major jurisdiction. Material is sold as a research chemical; that is a legal and supply-chain statement, not a finding that it has been shown to be harmful.

B7-33

Check jurisdiction-specific details in the profile.

Not an approved medicine in any major jurisdiction. Sale as a 'research chemical' is a legal and supply-chain statement, not evidence of benefit or harm.

Common claims

Cartalax

  • · Cartilage regeneration and joint repair
  • · Reversing osteoarthritis
  • · Meniscus and connective-tissue healing
  • · Anti-ageing and geroprotection

B7-33

  • · Anti-fibrotic effects in heart, lung or kidney
  • · Tissue repair and recovery

How settled our evidence rating is

Cartalax

Low confidence in ratingL0Anecdote only

B7-33

Low confidence in ratingL1Theory only

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Cartalax

Not established. Some of the reported cell-culture effects involve proliferation- and senescence-related pathways, which is a reason for caution rather than a finding of risk in either direction.

B7-33

Not established. No human data; no specific signal identified in the curated record.

What this adds up to, in plain English

Cartalax

This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.

B7-33

This sits in theory and anecdote. Popular claims about it should be treated with very low confidence.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.